Oppenheimer & CO Inc Vertex Pharmaceuticals Inc Transaction History

Oppenheimer & CO Inc

$6.42 Billion
Q3 2024

A detailed history of Oppenheimer & CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 13,128 shares of VRTX stock, worth $5.22 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

13,128

Previous 13,729 4.38%

Holding current value

$5.22 Million

Previous $6.44 Million 5.13%

% of portfolio

0.1%

Previous 0.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$460.0 - $505.78 $276,460 - $303,973	-601 Reduced 4.38%	13,128 $6.11 Million
Q2 2024 Aug 07, 2024	BUY	$392.81 - $485.53 $431,698 - $533,597	1,099 Added 8.7%	13,729 $6.44 Million
Q1 2024 May 06, 2024	BUY	$407.69 - $446.08 $307,398 - $336,344	754 Added 6.35%	12,630 $5.28 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $537,824 - $643,946	1,568 Added 15.21%	11,876 $4.83 Million
Q3 2023 Nov 07, 2023	BUY	$338.18 - $362.46 $607,709 - $651,340	1,797 Added 21.11%	10,308 $3.58 Million
Q2 2023 Aug 02, 2023	BUY	$314.42 - $351.91 $212,233 - $237,539	675 Added 8.61%	8,511 $3 Million
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $2.14 Million - $2.44 Million	-7,563 Reduced 49.11%	7,836 $2.47 Million
Q4 2022 Feb 07, 2023	SELL	$285.76 - $321.48 $310,906 - $349,770	-1,088 Reduced 6.6%	15,399 $4.45 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $258,769 - $288,725	945 Added 6.08%	16,487 $4.77 Million
Q2 2022 Aug 08, 2022	BUY	$234.96 - $292.55 $228,381 - $284,358	972 Added 6.67%	15,542 $4.38 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $1.51 Million - $1.78 Million	6,805 Added 87.64%	14,570 $3.8 Million
Q4 2021 Feb 02, 2022	BUY	$177.01 - $223.45 $768,223 - $969,773	4,340 Added 126.72%	7,765 $1.71 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $243,788 - $272,818	1,344 Added 64.58%	3,425 $621,000
Q2 2021 Aug 03, 2021	SELL	$187.49 - $221.1 $553,845 - $653,129	-2,954 Reduced 58.67%	2,081 $420,000
Q1 2021 May 10, 2021	SELL	$207.02 - $241.31 $482,770 - $562,734	-2,332 Reduced 31.65%	5,035 $1.08 Million
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $491,648 - $655,713	2,375 Added 47.58%	7,367 $1.74 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $948,972 - $1.13 Million	-3,712 Reduced 42.65%	4,992 $1.36 Million
Q2 2020 Aug 11, 2020	BUY	$225.48 - $295.8 $203,608 - $267,107	903 Added 11.58%	8,704 $2.53 Million
Q1 2020 May 08, 2020	BUY	$199.77 - $247.81 $462,068 - $573,184	2,313 Added 42.15%	7,801 $1.86 Million
Q4 2019 Feb 07, 2020	SELL	$166.71 - $223.91 $10,669 - $14,330	-64 Reduced 1.15%	5,488 $1.2 Million
Q3 2019 Oct 31, 2019	BUY	$166.23 - $187.09 $137,305 - $154,536	826 Added 17.48%	5,552 $941,000
Q2 2019 Aug 09, 2019	SELL	$164.61 - $190.37 $292,018 - $337,716	-1,774 Reduced 27.29%	4,726 $867,000
Q1 2019 Apr 24, 2019	SELL	$163.73 - $194.7 $215,304 - $256,030	-1,315 Reduced 16.83%	6,500 $1.2 Million
Q4 2018 Jan 29, 2019	SELL	$151.91 - $192.21 $560,092 - $708,678	-3,687 Reduced 32.06%	7,815 $1.3 Million
Q3 2018 Oct 26, 2018	BUY	$167.73 - $192.74 $553,844 - $636,427	3,302 Added 40.27%	11,502 $2.22 Million
Q2 2018 Aug 10, 2018	SELL	$145.72 - $169.96 $158,834 - $185,256	-1,090 Reduced 11.73%	8,200 $1.39 Million
Q1 2018 May 01, 2018	BUY	$151.6 - $177.13 $626,259 - $731,724	4,131 Added 80.07%	9,290 $1.51 Million
Q4 2017 Feb 07, 2018	BUY	$137.28 - $155.55 $98,017 - $111,062	714 Added 16.06%	5,159 $773,000
Q3 2017 Nov 09, 2017	BUY	$148.13 - $162.24 $658,437 - $721,156	4,445	4,445 $676,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Vertex Pharmaceuticals Inc Transaction History